DE69535917D1 - Verfahren zur Transfektion mittels Calciumphosphat - Google Patents

Verfahren zur Transfektion mittels Calciumphosphat

Info

Publication number
DE69535917D1
DE69535917D1 DE69535917T DE69535917T DE69535917D1 DE 69535917 D1 DE69535917 D1 DE 69535917D1 DE 69535917 T DE69535917 T DE 69535917T DE 69535917 T DE69535917 T DE 69535917T DE 69535917 D1 DE69535917 D1 DE 69535917D1
Authority
DE
Germany
Prior art keywords
mixt
particles
calcium phosphate
host cell
transfection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69535917T
Other languages
English (en)
Inventor
Florian M Wurm
Martin Jordan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69535917D1 publication Critical patent/DE69535917D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69535917T 1994-09-08 1995-08-30 Verfahren zur Transfektion mittels Calciumphosphat Expired - Lifetime DE69535917D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/303,245 US5484720A (en) 1994-09-08 1994-09-08 Methods for calcium phosphate transfection
US08/430,533 US5593875A (en) 1994-09-08 1995-04-26 Methods for calcium phosphate transfection

Publications (1)

Publication Number Publication Date
DE69535917D1 true DE69535917D1 (de) 2009-04-02

Family

ID=23171182

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69535917T Expired - Lifetime DE69535917D1 (de) 1994-09-08 1995-08-30 Verfahren zur Transfektion mittels Calciumphosphat

Country Status (4)

Country Link
US (3) US5484720A (de)
EP (1) EP1249497B1 (de)
AT (1) ATE423214T1 (de)
DE (1) DE69535917D1 (de)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484720A (en) * 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
GB9515356D0 (en) * 1995-07-26 1995-09-20 Medical Res Council Improvements in or relating to delivery of nucleic acid
US5843731A (en) * 1996-09-05 1998-12-01 Asahi Kogaku Kogyo Kabushiki Kaisha Method for purifying plasmid DNA on calcium phosphate compound
US5910584A (en) * 1996-09-05 1999-06-08 Asahi Kogaku Kogyo Kabushiki Kaisha Method for isolating plasmid DNA
AU9790998A (en) 1997-10-07 1999-04-27 Regents Of The University Of California Corporation Treating occlusive peripheral vascular disease and coronary disease with combinations of heparin and an adenoside a2 agonist, or with adenosine
US5972903A (en) * 1997-10-07 1999-10-26 Regents Of The University Of California Corporation Method for promoting angiogenesis using heparin and adenosine
US5973119A (en) * 1998-06-05 1999-10-26 Amgen Inc. Cyclin E genes and proteins
US6509174B2 (en) 1998-06-16 2003-01-21 Ecole Polytechnique Federal De Lausanne (Epfl) Cells, genetically modified with optical marker
GB9815819D0 (en) * 1998-07-22 1998-09-16 Secr Defence Transferring materials into cells and a microneedle array
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
DE69935252D1 (de) * 1998-12-23 2007-04-05 Genentech Inc Transfectaconen, die kalciumphosphat und eine nucleinsäure enthalten
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
EP1471034A3 (de) * 1999-02-03 2005-03-02 Biosante Pharmaceuticals, Inc. Therapeutische kalzium-phosphat Partikel und Methoden zu deren Herstellung und Verwendung
ATE276199T1 (de) * 1999-02-03 2004-10-15 Biosante Pharmaceuticals Inc Methoden zur herstellung von therapeutische kalzium-phosphat partikeln
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
SI1149114T1 (sl) * 1999-02-03 2014-08-29 Amgen Inc. Polipeptidi, vkljuäśeni v imunskem odgovoru
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
WO2000058479A1 (en) 1999-03-26 2000-10-05 Amgen Inc. Beta secretase genes and polypeptides
US7408047B1 (en) * 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6900043B1 (en) * 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
US20050239061A1 (en) * 2000-03-01 2005-10-27 Marshall William S Identification and use of effectors and allosteric molecules for the alteration of gene expression
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US7338773B2 (en) * 2000-04-14 2008-03-04 Millipore Corporation Multiplexed assays of cell migration
AU7161801A (en) * 2000-06-28 2002-01-08 Amgen Inc B7-like molecules and uses thereof
PT2077279E (pt) 2000-06-28 2012-09-14 Amgen Inc Moléculas do receptor de linfopoietina estromal tímica e suas utilizações
DK2364734T3 (en) * 2000-07-21 2017-10-30 Revance Therapeutics Inc Biological multicomponent transport systems
MXPA03004578A (es) 2000-11-28 2004-05-05 Amgen Inc Nuevos polipeptidos involucrados en respuesta inmune.
JP4607452B2 (ja) * 2001-08-07 2011-01-05 ダイナバックス テクノロジーズ コーポレイション 免疫調節性組成物、製剤およびその使用方法
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
US20080206202A1 (en) * 2001-09-24 2008-08-28 Christopher Reid Methods for application of endogenous or exogenous stem/progenitor or their progeny for treatment of disease
US20030109037A1 (en) * 2001-09-24 2003-06-12 Reid Christopher Brian Methods for application of genetically-modified endogenous or exogenous stem/progenitor or their progeny for treatment of disease
US7381375B2 (en) * 2001-10-26 2008-06-03 Millipore Corporation Assay systems with adjustable fluid communication
AU2002363076A1 (en) * 2001-10-26 2003-05-06 Virtual Arrays, Inc. Assay systems with adjustable fluid communication
US20080187949A1 (en) * 2001-10-26 2008-08-07 Millipore Corporation Multiplexed assays of cell migration
US7662924B2 (en) * 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US20040025194A1 (en) * 2002-02-22 2004-02-05 Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US20080207465A1 (en) * 2002-10-28 2008-08-28 Millipore Corporation Assay systems with adjustable fluid communication
KR100492292B1 (ko) * 2002-11-11 2005-05-27 오덕재 유전자의 세포내 도입을 위한 인산칼슘/핵산 복합체의 제조방법
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
CA2555921A1 (en) * 2004-02-13 2005-09-15 Nod Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of making and using same
EP2298896A1 (de) 2004-06-22 2011-03-23 The Board of Trustees of the University of Illinois Verfahren zur Inhibierung von Tumorzellwachstum mit FOXM1 siRNS
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008513356A (ja) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク． 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
CA2586035A1 (en) 2004-11-01 2006-05-11 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles in use for aesthetic or cosmetic medicine, and methods of manufacture and use
US20060257492A1 (en) * 2005-05-13 2006-11-16 Depuy Products, Inc. Suspension of calcium phosphate particulates for local delivery of therapeutic agents
US20060257358A1 (en) * 2005-05-13 2006-11-16 Depuy Products, Inc. Suspension of calcium phosphate particulates for local delivery of therapeutic agents
WO2007030674A2 (en) * 2005-09-07 2007-03-15 Maxcyte, Inc. Use of nucleases to improve viability and enhance transgene expression in transfected cells
HUE030872T2 (en) 2007-05-29 2017-06-28 Christopher B Reid Methods for producing multipotent cell populations, pluripotent cell populations, differentiated cell populations, and HIV-resistant cell populations and their applications
WO2009018250A2 (en) * 2007-07-30 2009-02-05 University Of Iowa Research Foundation Use of rpa4 and rpa4/rpa32 hybrid polypeptides for modulating cell proliferation
AR069573A1 (es) * 2007-12-05 2010-02-03 Monsanto Technology Llc Promotores de proteinas quimericas y ricas en prolina para la expresion en plantas, donde el fenotipo es una menor infeccion por patogenos
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
PE20120021A1 (es) 2008-10-10 2012-02-10 Amgen Inc Mutantes fgf21
MX2011011815A (es) 2009-05-05 2012-01-27 Amgen Inc Mutantes fgf21 y usos de los mismos.
CN107188950B (zh) 2009-05-05 2021-09-28 安姆根有限公司 Fgf21突变体及其用途
EP2443145A1 (de) * 2009-06-17 2012-04-25 Amgen, Inc Chimäre fgf19-polypeptide und ihreverwendung
CA2780671A1 (en) 2009-11-05 2011-05-12 Proyecto De Biomedicina Cima, S.L. Regulated expression system
EP2679234A3 (de) * 2009-12-02 2014-04-23 Amgen Inc. Bindeproteine zur Bindung an humanem FGFR1C, humanem beta-Klotho sowie humanem FGFR1C als auch humanem beta-Klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
EP2571987B1 (de) 2010-05-21 2017-03-01 Peptimed, Inc. Reagenzien zur behandlung von krebs
WO2012095548A2 (es) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
US9493744B2 (en) 2012-06-20 2016-11-15 Genentech, Inc. Methods for viral inactivation and other adventitious agents
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018112456A1 (en) * 2016-12-16 2018-06-21 Delphi Scientific, Llc Layered particles and processes thereof
SG11202004457XA (en) 2017-11-17 2020-06-29 Iovance Biotherapeutics Inc Til expansion from fine needle aspirates and small biopsies
CA3083118A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
EP3737743A1 (de) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Verfahren zur erzeugung von til-produkten, die für tumorantigenspezifische t-zellen angereichert sind
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
US20190300575A1 (en) 2018-03-29 2019-10-03 Deetex, LLC Lytic peptide biosensor and methods of making and using the same
MA52533A (fr) 2018-04-27 2021-03-03 Iovance Biotherapeutics Inc Procédé en circuit fermé pour l'amplification et l'edition de gènes de lymphocytes d'infiltration des tumeurs et leurs utilisations en immunothérapie
KR20210053285A (ko) * 2018-08-16 2021-05-11 스페이스크래프트 세븐, 엘엘씨 바이러스 벡터의 생산 방법
JP2022506508A (ja) 2018-11-05 2022-01-17 アイオバンス バイオセラピューティクス，インコーポレイテッド Ａｋｔ経路阻害剤を利用したｔｉｌの拡大培養
BR112021008266A2 (pt) 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Métodos para expandir linfócitos infiltrantes de tumor em uma população terapêutica de linfócitos infiltrantes de tumor e para tratar um sujeito com câncer, e, população terapêutica de linfócitos infiltrantes de tumor
PE20211292A1 (es) 2018-11-05 2021-07-20 Iovance Biotherapeutics Inc Procesos para la produccion de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia
CN112969469A (zh) 2018-11-05 2021-06-15 艾欧凡斯生物治疗公司 抗pd-1抗体难治性nsclc患者的治疗
JP2022514023A (ja) 2018-12-19 2022-02-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
JP2022522473A (ja) 2019-03-01 2022-04-19 アイオバンス バイオセラピューティクス，インコーポレイテッド 液性腫瘍からの腫瘍浸潤リンパ球の拡大培養及びその治療的使用
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP4048295A1 (de) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Genbearbeitung von tumorinfiltrierenden lymphozyten und deren verwendungen in der immuntherapie
CA3161104A1 (en) 2019-12-11 2021-06-17 Cecile Chartier-Courtaud Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
TW202208617A (zh) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 用於產生腫瘤浸潤性淋巴球的過程及其在免疫療法中的用途
TW202208616A (zh) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 改良之腫瘤反應性ｔ細胞的選擇
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
WO2022125941A1 (en) 2020-12-11 2022-06-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
EP4262827A1 (de) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Behandlung von krebs mit tumorinfiltrierenden lymphozyten
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
CA3206549A1 (en) 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
TW202304480A (zh) 2021-03-19 2023-02-01 美商艾歐凡斯生物治療公司 腫瘤浸潤淋巴球（ｔｉｌ）中之與ｃｄ３９／ｃｄ６９選擇及基因剔除相關之ｔｉｌ擴增之方法
JP2024511414A (ja) 2021-03-23 2024-03-13 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球のｃｉｓｈ遺伝子編集及び免疫療法におけるその使用
CA3215830A1 (en) 2021-04-19 2022-10-27 Rafael CUBAS Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2022245754A1 (en) 2021-05-17 2022-11-24 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2023004074A2 (en) 2021-07-22 2023-01-26 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
KR20240109615A (ko) 2021-09-09 2024-07-11 이오반스 바이오테라퓨틱스, 인크. Pd-1 talen 녹다운을 사용한 til 생성물의 생성 방법
AR127482A1 (es) 2021-10-27 2024-01-31 Iovance Biotherapeutics Inc Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
WO2023086803A1 (en) 2021-11-10 2023-05-19 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023196877A1 (en) 2022-04-06 2023-10-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023220608A1 (en) 2022-05-10 2023-11-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024055017A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2024055018A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2024098027A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024112711A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Methods for assessing proliferation potency of gene-edited t cells
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0430930B1 (de) * 1985-03-15 1993-09-01 Btg International Limited Faktor IX-Protein
US4968615A (en) * 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5484720A (en) * 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection

Also Published As

Publication number Publication date
US5484720A (en) 1996-01-16
EP1249497A3 (de) 2004-03-17
EP1249497A2 (de) 2002-10-16
ATE423214T1 (de) 2009-03-15
EP1249497B1 (de) 2009-02-18
US5633156A (en) 1997-05-27
US5593875A (en) 1997-01-14

Similar Documents

Publication Publication Date Title
DE69535917D1 (de) Verfahren zur Transfektion mittels Calciumphosphat
Deininger Random subcloning of sonicated DNA: application to shotgun DNA sequence analysis
DE69432540D1 (de) Verfahren zur Herstellung von Nucleinsäuren aus einer biologischen Probe bei niedrigem pH und unter Verwendung einer Säureprotease
AR245776A1 (es) Metodo para la modificacion de las caracteristicas de expresion de un gen endogeno de un microorganismo o una linea celular determinada.
ATE181364T1 (de) Verfahren zur stabile transformation von weizen
ATE411391T1 (de) Verfahren zur herstellung stresstoleranter pflanzen
DE3674861D1 (de) 7-desaza-2'-desoxyguanosin-nukleotide, verfahren zu deren herstellung und deren verwendung zur nukleinsaeure-sequenzierung.
HUP0300822A2 (hu) Eljárás szilárd herbicid formulációk előállítására
ATE213019T1 (de) Chimäre oligomere mit einer rns- spaltungsaktivität
DE69936532D1 (de) Verfahren zum quantitativen nachweis von nukleinsäuren
DE69535865D1 (de) Transferase und Amylase, Verfahren zur Herstellung dieser Enzyme, ihre Verwendung und kodierende Gene
ATE297469T1 (de) Verfahren zur polyestern-biosynthese
ATE310816T1 (de) Verfahren zur bestimmung einer genfunktion
DK1141366T3 (da) Transfektaconer omfattende calciumphosphat og en nukleinsyre
ATE228170T1 (de) Verfahren zur kalziumphosphat-transfektion
ATE298747T1 (de) Verfahren zur herstellung von 5- hydroxybenzo(b)thiophen-3-carbonsäure
WO2002092786A3 (en) A helper dependent adenoviral vector system and methods for using the same
AU1721600A (en) Compositions and methods for recombinational cloning of nucleic acid molecules
BR9808472A (pt) Método de produção de proteìna heteróloga
DE69519388D1 (de) Verfahren zur herstellung von 2-(omega-alkoxycarbonylalkanoyl)-4-butanolid und langkettiger omega-hydroxycarbonsäure
BR9811541A (pt) ésteres de ácido hidroxialquilcelulose-2-hidroxicarboxìlicos hidrossolúveis, floculáveis e biologicamente degradáveis
US5330904A (en) Method for mammalian cell transfection using 25-hydroxycholesterol
DE69924718D1 (de) Gen 62 des attenuierten windpocken-virusstammes oka und verfahren zur identifikation eines attenuierten, lebenden windpockenvirusstammes unter verwendung dieses genes.
WO2000000598A3 (en) Plant dwarfing
DE69408319D1 (de) Verfahren zur herstellung von einer omega-funktionalisierten aliphatischen carbonsäure und zwischenprodukte dieses verfahrens

Legal Events

Date Code Title Description
8364 No opposition during term of opposition